Pre-made Tesnatilimab benchmark antibody ( Whole mAb, anti-KLRK1 therapeutic antibody, Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-566

Pre-Made Tesnatilimab biosimilar, Whole mAb, Anti-KLRK1 Antibody: Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tesnatilimab (formerly JNJ 4500) is being developed by Janssen Biotech, for the treatment of autoimmune diseases, including Crohn's disease.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-566-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Tesnatilimab biosimilar, Whole mAb, Anti-KLRK1 Antibody: Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D therapeutic antibody
INN Name Tesnatilimab
TargetKLRK1
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesJanssen Research & Development
Conditions Approvedna
Conditions ActiveCrohn's disease
Conditions Discontinuedna
Development Techna